Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds

Healthy Volunteers Clinical Trial

Official title:

Randomized, Exploratory Study to Evaluate Changes to Skin Microbiome With Tape-stripped Wounds

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03365934
• Other study ID #: CO-170726100607-SACT
• Status: Completed
• Phase: N/A
• Start date: November 20, 2017
• Est. completion date: February 12, 2018

Study information

• Verified date: May 2019
• Source: Johnson & Johnson Consumer and Personal Products Worldwide
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This single center, randomized, 15-day clinical trial is being conducted to assess the changes to the skin microbiome of induced wounds on the back in approximately 35 healthy adult subjects aged 18-55 years, with Fitzpatrick Skin Types I - III. Microbiome and skin physiology assessments will be completed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: February 12, 2018
• Est. primary completion date: February 12, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Adults aged 18 to 55 years of age.

2. Fitzpatrick skin types I to III.

3. Must be able to comprehend and follow the requirements of the study

4. Avoid excessive sun exposure

5. Willing to refrain from topical product use on the back for the duration of the study.

6. Subjects must agree not to immerse their bandages in water for the duration of the study.

7. Male and female subjects with reproductive potential who agree to practice a medically acceptable form of birth control

Exclusion Criteria:

1. Excessively hairy back, acne, scars and pigmentation or nevi t

2. . Pregnant or Lactating, or planning on becoming pregnant;

3. . Known allergies or sensitivities to anesthetics, adhesive bandages, wound treatment products or tapes;

4. . Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results

5. Participation in any other clinical study within 30 days of Visit 1;

6. . Subjects who have a health condition and/or pre-existing or dormant dermatologic conditions or who have clinically active bacterial, fungal, or viral skin infections or those who are susceptible to cutaneous infections

7. Subjects who report using prescription or OTC medication (oral or topical) that can make skin more sensitive or influence the skin (i.e. antibiotics, hormones, insulin, etc.)

8. Subjects receiving topical and/or inhaled medications that may alter or compromise the bleeding/healing process

9. Individuals with a history of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications and/or radiation

10. . Subjects with a known history of keloid or hypertrophic scar formation;

11. Subjects diagnosed with any blood clotting disorder;

12. Hyperthyroidism or hypothyroidism or with active or recently treated (within 1 year) skin cancer, or those in poor nutritional status; 13 Subjects taking oral Vitamin A derivatives such as Accutane, isotretinon, or using retinoic acid in the past 1 year or using topical Vitamin A derivatives in the 3 weeks prior to study start;

14. Subjects with clinically infected skin lesions; 15. Subjects with cracked or excoriated skin, or other skin problems. 16. Diabetes mellitus that cannot be controlled by diet alone (i.e. requires systemic medications for control); 17. Subjects with friable skin, at the discretion of the Investigator;

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Device:
• ADHESIVE BANDAGE #1
Bandage applied daily to wounded site for 14 days
• ADHESIVE BANDAGE #2
Bandage applied daily to wounded site for 14 days
• ADHESIVE BANDAGE #3
Bandage applied daily to wounded site for 14 days
• Antibacterial Bandage with 0.8% BZK
bandage with 0.8% Benzalkonium Chloride (BZK) applied daily to wounded site for 14 days

Other:
• Intact and No Bandage
This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
• Wounded and No Bandage
This test site will be wounded but will not be treated with a bandage, serving as the positive control site.

Locations

Country	Name	City	State
United States	TKL Research Inc.	Fair Lawn	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Johnson & Johnson Consumer Inc. (J&JCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Microbial Community Richness - Baseline (Day 0)	Swabs will be collected on the back at Baseline (Day 0) and analyzed to determine the total number of different bacterial taxa (microorganisms) detected in the sample. There was no prespecified primary endpoint in the protocol.	Baseline (Day 0)
Primary	Microbial Community Richness - (Day 1)	Swabs will be collected on the back at Day 1 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.	Day 1
Primary	Microbial Community Richness - (Day 2)	Swabs will be collected on the back at Day 2 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.	Day 2
Primary	Microbial Community Richness - (Day 3)	Swabs will be collected on the back at Day 3 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.	Day 3
Primary	Microbial Community Richness - (Day 4)	Swabs will be collected on the back at Day 4 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.	Day 4
Primary	Microbial Community Richness - (Day 5)	Swabs will be collected on the back at Day 5 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.	Day 5
Primary	Microbial Community Richness - (Day 6)	Swabs will be collected on the back at Day 6 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.	Day 6
Primary	Microbial Community Richness - (Day 7)	Swabs will be collected on the back at Day 7 and analyzed to determine the total number of different bacteria Taxa (microorganismss) detected in the sample.	Day 7
Primary	Microbial Community Richness - (Day 14)	Swabs will be collected on the back at Day 14 and analyzed to determine the total number of different bacteria Taxa (microorganisms) detected in the sample.	Day 14
Primary	Microbial Community Diversity - Baseline (Day 0)	Swabs will be collected on the back at Baseline (Day 0) for analysis based on the Shannon Index.	Baseline (Day 0)
Primary	Microbial Community Diversity - Day 1	Swabs will be collected on the back at Day 1 for analysis based on the Shannon Index.	Day 1
Primary	Microbial Community Diversity - Day 2	Swabs will be collected on the back at Day 2 for analysis based on the Shannon Index.	Day 2
Primary	Microbial Community Diversity - Day 3	Swabs will be collected on the back at Day 3 for analysis based on the Shannon Index.	Day 3
Primary	Microbial Community Diversity - Day 4	Swabs will be collected on the back at Day 4 for analysis based on the Shannon Index.	Day 4
Primary	Microbial Community Diversity - Day 5	Swabs will be collected on the back at Day 5 for analysis based on the Shannon Index.	Day 5
Primary	Microbial Community Diversity - Day 6	Swabs will be collected on the back at Day 6 for analysis based on the Shannon Index.	Day 6
Primary	Microbial Community Diversity - Day 7	Swabs will be collected on the back at Day 7 for analysis based on the Shannon Index.	Day 7
Primary	Microbial Community Diversity - Day 14	Swabs will be collected on the back at Day 14 for analysis based on the Shannon Index.	Day 14
Primary	Microbial Community Evenness - Baseline (Day 0)	Swabs will be collected on the back at Baseline (Day 0) for analysis based on the Pielou's Evenness Index.	Day 0
Primary	Microbial Community Evenness - Day 1	Swabs will be collected on the back at Day 1 for analysis based on the Pielou's Evenness Index.	Day 1
Primary	Microbial Community Evenness - Day 2	Swabs will be collected on the back at Day 2 for analysis based on the Pielou's Evenness Index.	Day 2
Primary	Microbial Community Evenness - Day 3	Swabs will be collected on the back at Day 3 for analysis based on the Pielou's Evenness Index.	Day 3
Primary	Microbial Community Evenness - Day 4	Swabs will be collected on the back at Day 4 for analysis based on the Pielou's Evenness Index.	Day 4
Primary	Microbial Community Evenness - Day 5	Swabs will be collected on the back at Day 5 for analysis based on the Pielou's Evenness Index.	Day 5
Primary	Microbial Community Evenness - Day 6	Swabs will be collected on the back at Day 6 for analysis based on the Pielou's Evenness Index.	Day 6
Primary	Microbial Community Evenness - Day 7	Swabs will be collected on the back at Day 7 for analysis based on the Pielou's Evenness Index.	Day 7
Primary	Microbial Community Evenness - Day 14	Swabs will be collected on the back at Day 14 for analysis based on the Pielou's Evenness Index.	Day 14
Secondary	Skin Barrier Function -Baseline (Day 0)	The skin barrier function of the test sites will be evaluated at Baseline (Day 0) by Trans Epidermal Water Loss (TEWL).	Day 0
Secondary	Skin Barrier Function - Day 1	The skin barrier function of the test sites will be evaluated at Day 1 by Trans Epidermal Water Loss (TEWL).	Day 1
Secondary	Skin Barrier Function - Day 2	The skin barrier function of the test sites will be evaluated at Day 2 by Trans Epidermal Water Loss (TEWL).	Day 2
Secondary	Skin Barrier Function - Day 3	The skin barrier function of the test sites will be evaluated at Day 3 by Trans Epidermal Water Loss (TEWL).	Day 3
Secondary	Skin Barrier Function - Day 4	The skin barrier function of the test sites will be evaluated at Day 4 by Trans Epidermal Water Loss (TEWL).	Day 4
Secondary	Skin Barrier Function - Day 5	The skin barrier function of the test sites will be evaluated at Day 5 by Trans Epidermal Water Loss (TEWL).	Day 5
Secondary	Skin Barrier Function - Day 6	The skin barrier function of the test sites will be evaluated at Day 6 by Trans Epidermal Water Loss (TEWL).	Day 6
Secondary	Skin Barrier Function - Day 7	The skin barrier function of the test sites will be evaluated at Day 7 by Trans Epidermal Water Loss (TEWL).	Day 7
Secondary	Skin Barrier Function - Day 14	The skin barrier function of the test sites will be evaluated at Day 14 by Trans Epidermal Water Loss (TEWL).	Day 14
Secondary	Redness: Wound Area Oxyhemoglobin Level- Baseline (Day 0)	Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.	Day 0
Secondary	Redness: Wound Area Oxyhemoglobin Level - Day 1	Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.	Day 1
Secondary	Redness: Wound Area Oxyhemoglobin Level - Day 2	Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.	Day 2
Secondary	Redness: Wound Area Oxyhemoglobin Level - Day 3	Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.	Day 3
Secondary	Redness: Wound Area Oxyhemoglobin Level - Day 4	Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.	Day 4
Secondary	Redness: Wound Area Oxyhemoglobin Level - Day 5	Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.	Day 5
Secondary	Redness: Wound Area Oxyhemoglobin Level - Day 6	Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.	Day 6
Secondary	Redness: Wound Area Oxyhemoglobin Level - Day 7	Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.	Day 7
Secondary	Redness: Wound Area Oxyhemoglobin Level - Day 14	Quantification of oxy- and deoxy-hemoglobin at the wound area was achieved from apparent absorption spectrum acquired from diffuse reflectance spectroscopy (DRS) at the site. Absorption spectra of fully oxygenated and deoxygenated hemoglobin molecules were employed to quantify the contribution of each molecule to the total apparent absorption of the wounded skin in the spectral range of 560 nm -- 700 nm. The numbers of oxyhemoglobin are in arbitrary unit and higher values describe higher erythema levels.	Day 14